Abstract
The 40th ICAAC Meeting provided one of the widest varieties of new antibacterial and antifungal agents in years, with a range of improved ‘classical’ agents (Β-lactams, carbapenems), novel quinolone agents and totally new ideas for novel therapeutic intervention. Among the compounds reported were potent anti-MRSA carbapenems, novel des-fluoroquinolones (BMS 284756/T-3811), non-fluorinated quinolones, quinolone-related antibacterials, novel cephalosporins (cefditoren, RWJ-54428, MC 04546), ketolides (telithromycin, ABT-773), novel streptogramins and novel Β-lactamase inhibitors, bacterial and fungal efflux pump inhibitors and novel antifungals (azasordarins, echinocandins, azoles).